NASDAQ:PLXPPLx Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PLx Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.68 -0.23 (-5.88 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.33Now: $3.68▼$4.0850-Day Range$2.33MA: $2.76▼$4.1452-Week Range$1.80Now: $3.68▼$7.41Volume44,503 shsAverage Volume24,070 shsMarket Capitalization$33.71 millionP/E RatioN/ADividend YieldN/ABeta4.24 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. The company was founded in 2002 and is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for PLx Pharma. Previous Next 2.1 Community Rank Outperform VotesPLx Pharma has received 173 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPLx Pharma has received 239 “underperform” votes. (Add your “underperform” vote.)Community SentimentPLx Pharma has received 58.01% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote “Outperform” if you believe PLXP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPLx Pharma does not currently pay a dividend.Dividend GrowthPLx Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PLx Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.79% of the stock of PLx Pharma is held by insiders.Percentage Held by InstitutionsOnly 22.35% of the stock of PLx Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PLx Pharma are expected to grow in the coming year, from ($1.44) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PLx Pharma is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PLx Pharma is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLXP Previous Symbol CUSIPN/A CIK1497504 Webwww.plxpharma.com Phone973-409-6541Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$570,000.00 Price / Sales59.14 Cash FlowN/A Price / Cash FlowN/A Book Value($1.16) per share Price / Book-3.17Profitability EPS (Most Recent Fiscal Year)($4.74) Net Income$-20,500,000.00 Net Margins-3,369.72% Return on EquityN/A Return on Assets-74.61%Miscellaneous Employees12 Outstanding Shares9,160,000Market Cap$33.71 million Next Earnings Date8/14/2020 (Estimated) OptionableNot Optionable NASDAQ:PLXP Rates by TradingView Receive PLXP News and Ratings via Email Sign-up to receive the latest news and ratings for PLXP and its competitors with MarketBeat's FREE daily newsletter. PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions How has PLx Pharma's stock been impacted by COVID-19 (Coronavirus)? PLx Pharma's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PLXP shares have decreased by 23.5% and is now trading at $3.68. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of PLx Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PLx Pharma. When is PLx Pharma's next earnings date? PLx Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for PLx Pharma. How were PLx Pharma's earnings last quarter? PLx Pharma Inc (NASDAQ:PLXP) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.37) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.03. View PLx Pharma's earnings history. Has PLx Pharma been receiving favorable news coverage? News coverage about PLXP stock has trended somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PLx Pharma earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPLx Pharma. Who are some of PLx Pharma's key competitors? Some companies that are related to PLx Pharma include Zynerba Pharmaceuticals (ZYNE), AVEO Pharmaceuticals (AVEO), Endonovo Therapeutics (ENDV), SUMMIT THERAPEU/S (SMMT), Savara (SVRA), GlycoMimetics (GLYC), Theratechnologies (THERF), Axovant Gene Therapies (AXGT), Checkpoint Therapeutics (CKPT), OASMIA PHARMACE/ADR (OASM), InflaRx (LUMO), AcelRx Pharmaceuticals (ACRX), Catabasis Pharmaceuticals (CATB), Cyclerion Therapeutics (CYCN) and ESSA Pharma (EPIX). View all competitors. What other stocks do shareholders of PLx Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), Abeona Therapeutics (ABEO), Arlington Asset Investment (AI), CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals (CRBP), Ford Motor (F) and Medley Capital (MCC). Who are PLx Pharma's key executives? PLx Pharma's management team includes the following people: Mr. Michael J. Valentino, Exec. Chairman (Age 65)Ms. Natasha Giordano, CEO, Pres & Director (Age 59)Mr. Gary L. Mossman, Sr. Advisor (Age 78)Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51) When did PLx Pharma IPO? (PLXP) raised $68 million in an initial public offering (IPO) on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers. What is PLx Pharma's stock symbol? PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP." Who are PLx Pharma's major shareholders? PLx Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Heritage Way Advisors LLC (0.46%). Company insiders that own PLx Pharma stock include Michael J Valentino and Park West Asset Management Llc. View institutional ownership trends for PLx Pharma. Which institutional investors are buying PLx Pharma stock? PLXP stock was bought by a variety of institutional investors in the last quarter, including Heritage Way Advisors LLC. Company insiders that have bought PLx Pharma stock in the last two years include Michael J Valentino, and Park West Asset Management Llc. View insider buying and selling activity for PLx Pharma. How do I buy shares of PLx Pharma? Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PLx Pharma's stock price today? One share of PLXP stock can currently be purchased for approximately $3.68. How big of a company is PLx Pharma? PLx Pharma has a market capitalization of $33.71 million and generates $570,000.00 in revenue each year. The biotechnology company earns $-20,500,000.00 in net income (profit) each year or ($4.74) on an earnings per share basis. PLx Pharma employs 12 workers across the globe. What is PLx Pharma's official website? The official website for PLx Pharma is www.plxpharma.com. How can I contact PLx Pharma? PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 973-409-6541 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
